Piclidenoson is under clinical advancement by Can-Fite BioPharma and as of now in Stage III for Plaque Psoriasis (Psoriasis Vulgaris). As per GlobalData, Stage III medications for Plaque Psoriasis (Psoriasis Vulgaris) have a 81% stage change achievement rate (PTSR) sign benchmark for advancing into Pre-Enlistment. GlobalData's report evaluates how Piclidenoson's medication explicit PTSR and...